Mean change in visual acuity at 1 year (number of letters) · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in mean change in visual acuity at 1 year (number of letters) compared with ranibizumab (high certainty).
1 finding from 1 review
Reduction in central retinal thickness at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in reduction in central retinal thickness at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
No problems in quality of life domains at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in no problems in quality of life domains at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
RR 0.51 [0.05, 5.62]
1670 participants
Moderate
BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in gain of 15 or more letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in loss of fewer than 15 letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
Improvement in central macular thickness on OCT · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Significant intraocular inflammation at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of cataract at · adults with centre‐involving diabetic macular oedema
It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes development of cataract at compared with macular laser (very low certainty).
1 finding from 1 review
Raised Intraocular Pressure at · adults with centre‐involving diabetic macular oedema
It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes raised Intraocular Pressure at compared with macular laser (very low certainty).
1 finding from 1 review
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Gain or loss of 10 or more letters visual acuity at 1 year · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in central macular thickness on OCT · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Significant intraocular inflammation at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of cataract at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Raised Intraocular Pressure at · adults with centre‐involving diabetic macular oedema
It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes raised intraocular pressure at 1 year at compared with intravitreal steroid (very low certainty).
1 finding from 1 review
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found